Rh Incompatibility, explained for the bedside and the exam

Defining it precisely

Rh incompatibility is a maternal-fetal blood group mismatch. The mother is Rh-negative, lacking the D antigen on her red blood cells. The fetus, having inherited an Rh-positive allele from the father, carries the D antigen. When fetal blood crosses into the maternal circulation, the mother's immune system recognises the D antigen as foreign and produces anti-D antibodies. This is alloimmunisation, not an allergy and not a genetic disorder in the fetus itself.

The clinical consequence is haemolytic disease of the fetus and newborn. Maternal anti-D antibodies are IgG, small enough to cross the placenta. In a sensitised pregnancy, they attack fetal red blood cells, causing haemolysis, fetal anaemia, and in severe cases hydrops fetalis. The severity tends to worsen with each subsequent Rh-positive pregnancy because antibody titres rise with repeated exposure. This progressive pattern is central to how the condition is taught and tested.

The exceptions that matter

The first pregnancy sensitises and the second is at risk, which is why the timing of RhoGAM matters so much. During a first Rh-positive pregnancy, the mother has not yet been exposed to the D antigen, so no antibodies exist at the start. Fetomaternal haemorrhage, the mixing of fetal and maternal blood, typically happens in small amounts throughout pregnancy but most significantly at delivery, when the placenta separates. That exposure sensitises the mother after the baby is already born, so the first infant is usually unaffected.

The exception nurses must not miss is any event that causes earlier fetomaternal haemorrhage, such as amniocentesis, chorionic villus sampling, abdominal trauma, ectopic pregnancy, miscarriage, or antepartum bleeding. Each of these can sensitise a mother mid-pregnancy, well before delivery, and each requires RhoGAM administration at the time of the event, not just as routine prophylaxis at 28 weeks and postpartum. A mother who has already been sensitised in a prior pregnancy will not benefit from RhoGAM in a current one; the antibodies are already present.

Using it to prioritise

When assessing an Rh-negative pregnant patient, the priority sequence starts with confirming maternal Rh status and antibody screen (indirect Coombs test) at the first prenatal visit. A negative antibody screen means RhoGAM can still work; a positive screen means the mother is already sensitised and RhoGAM is no longer indicated for that antigen. This distinction drives every subsequent decision, so it comes before anything else in triage.

Next, prioritise identifying any bleeding or invasive procedure event, since these change the RhoGAM administration timeline outside the standard 28-week and postpartum doses. After delivery, confirm the newborn's blood type and Rh status promptly; if the infant is Rh-positive, the mother receives RhoGAM within 72 hours. Fetal surveillance for anaemia, via middle cerebral artery Doppler in high-risk sensitised pregnancies, takes priority over routine monitoring once antibody titres are elevated, because it guides decisions about intrauterine transfusion or early delivery.

Traps in exam wording

NCLEX-style items often test whether you know that RhoGAM is prophylaxis, not treatment. If a question describes a mother who is already sensitised, with a positive indirect Coombs test, RhoGAM is not the correct intervention; it does nothing once antibodies exist. Distractors frequently offer RhoGAM as the answer regardless of sensitisation status, banking on the reader missing that detail.

Another common trap swaps which pregnancy is at risk. Questions may describe a first pregnancy with severe fetal haemolysis to test whether you recognise this as atypical, or they describe a second pregnancy with mild symptoms and expect you to flag inconsistency. Watch for scenarios involving miscarriage, abortion, or ectopic pregnancy in an Rh-negative patient; test-writers use these to check whether you know RhoGAM applies here too, not only to full-term deliveries. Finally, distinguish Rh incompatibility from ABO incompatibility; ABO reactions can occur in a first pregnancy and are generally milder, and confusing the two is a frequent scoring trap.

Examples from practice

An Rh-negative primigravida at 28 weeks with a negative antibody screen receives a routine prophylactic dose of RhoGAM. She delivers an Rh-positive infant and receives a second dose within 72 hours. This is the standard, uncomplicated pathway and the one most questions build outward from.

A different scenario: an Rh-negative woman in her second pregnancy has a positive indirect Coombs test from a prior unrecognised sensitising event, perhaps a miscarriage that went untreated. Her current fetus shows rising middle cerebral artery Doppler velocities on ultrasound, indicating fetal anaemia. RhoGAM offers no benefit here; management shifts to serial titres, specialist referral, and possible intrauterine transfusion. Recognising which pathway a patient is on, prophylactic versus already-sensitised, is the practical skill this condition demands.

Summary

Rh incompatibility arises when an Rh-negative mother is exposed to Rh-positive fetal blood and develops anti-D antibodies. The first pregnancy sensitises and the second is at risk, which is why RhoGAM must be given proactively, at 28 weeks and within 72 hours postpartum, and immediately after any bleeding or invasive procedure that could cause fetomaternal haemorrhage. Once sensitisation has occurred, RhoGAM cannot reverse it, and care shifts to monitoring and managing an already-immunised pregnancy.